Guardant Health, Inc.(GH)Stock Performance & ReturnsNASDAQ
Returns, drawdowns and benchmark comparison
Peer Comparison
Relative scale, growth, and profitability vs sector peers
| Ticker | Market Cap | P/E Ratio | Revenue Growth | Net Margin | EPS | ROE | Debt/Equity | Dividend Yield | 52W High | 52W Low |
|---|---|---|---|---|---|---|---|---|---|---|
GH | 22.59 B | - | 44.30% | -38.33% | -$3.44 | - | - | 0.00% | $183.51 | $61.00 |
CVS | 112.49 B | 23.33x | 7.10% | 1.18% | $3.77 | 6.21% | 0.95x | 3.12% | $110.00 | $68.48 |
CI | 73.59 B | 11.68x | 6.70% | 2.27% | $23.85 | 16.76% | 0.74x | 2.29% | $308.48 | $234.20 |
LH | 25.30 B | 25.83x | 5.80% | 6.99% | $12.08 | 11.73% | 0.79x | 0.95% | $341.07 | $242.07 |
DGX | 25.06 B | 24.10x | 10.20% | 9.19% | $9.42 | 14.60% | 0.81x | 1.44% | $248.84 | $168.97 |
Peer Valuation & Performance Analysis
Peer group analysis for Guardant Health, Inc. (GH) compared to its primary competitors (including CVS, CI, LH) reveals distinct metrics. GH trades at a valuation discount relative to its competitors, with a P/E ratio of -48.9x versus the peer average of 21.2x (representing a 330% discount). This discount might represent an undervalued entry opportunity or reflect specific risk factors the market is discounting. In terms of growth, GH's revenue growth of 44.3% exceeds the peer average of 7.5%, highlighting its competitive strength and market share gains. Additionally, its net margin of -38.3% is below the peer average of 4.9%, suggesting higher operational costs or lower pricing power relative to peers.
Peer Performance Rankings
Ranking comparison across key performance metrics
P/E Ratio (Lower is Better)
Revenue Growth
Net Profit Margin
Financial Rankings Summary
• GH ranks #0 in P/E ratio, #1 in revenue growth, and #5 in profit margins
• Average ranking: #2 - 🎯 Top-tier fundamentals relative to peer group
• Rankings based on actual financial data from company reports
Historical Trading Data
Price and volume data with customizable timeframes
Showing 15 of 15 trading sessions from the last 15 days
| Date | Open | High | Low | Close | Volume | Daily Change |
|---|---|---|---|---|---|---|
| 2026-10-07 | $166.50 | $171.55 | $165.00 | $168.33 | 2,200,600 | -1.38% |
| 2026-10-06 | $188.00 | $191.05 | $170.05 | $170.69 | 3,386,200 | -8.83% |
| 2026-10-05 | $177.45 | $187.69 | $176.37 | $187.22 | 1,738,400 | +5.30% |
| 2026-10-02 | $173.32 | $179.17 | $172.00 | $177.80 | 1,650,700 | +1.75% |
| 2026-10-01 | $177.17 | $180.91 | $173.96 | $174.75 | 1,961,100 | -2.02% |
| 2026-09-30 | $177.75 | $180.34 | $175.33 | $178.36 | 1,576,200 | +0.35% |
| 2026-09-29 | $176.78 | $180.90 | $174.54 | $177.73 | 1,658,500 | +0.23% |
| 2026-09-28 | $174.85 | $180.05 | $174.69 | $177.33 | 1,318,500 | +0.05% |
| 2026-09-25 | $178.50 | $179.97 | $174.50 | $177.25 | 1,578,400 | +0.45% |
| 2026-09-24 | $174.05 | $181.79 | $173.50 | $176.45 | 2,571,700 | +0.08% |
| 2026-09-23 | $176.21 | $179.35 | $174.17 | $176.31 | 1,431,300 | -0.48% |
| 2026-09-22 | $172.40 | $179.43 | $170.50 | $177.16 | 2,226,400 | +1.89% |
| 2026-09-21 | $181.37 | $181.37 | $172.86 | $173.87 | 2,623,900 | -3.07% |
| 2026-09-18 | $183.00 | $183.50 | $175.62 | $179.38 | 3,080,700 | -2.03% |
| 2026-09-17 | $177.49 | $183.51 | $175.45 | $183.10 | 1,858,400 | +4.69% |
Explore More Analysis for GH
Additional research, tools, and technical breakdowns
Stock Analyzer Report
Deep-dive automated research and stock rating report.
DCF Fair Value Calculator
Discounted cash flow model and intrinsic value projection.
AI Price Predictions
Multi-scenario price predictions and consensus targets.
Insider Activity Tracker
Track buying/selling behavior of corporate insiders.
Earnings Calendar
Track upcoming and historical corporate earnings reports.
Market Insights & Research
Read the latest analysis articles and expert research.